InterVest
VC Fund
Kirkland, United States
InterVest is a VC fund in Kirkland focused on Health Care and Software. InterVest offers a range of marketing and financial technology services to companies in Gibraltar.
- Total investments:
- 35
- Last investment:
- Lead investor:
- 23%
Last updated:
For AI agents: llms.txt
Industries InterVest invests in
Stages InterVest invests in
Countries InterVest invests in
Round sizes
Round size
- Series A
- $2.5M–$36M
- Series B
- $3M–$30M
- Series C
- $14M–$75M
Investment Focus
Industry
- Health Care 11 (31%)
- Software 7 (20%)
- Biotechnology 6 (17%)
- Therapeutics 5 (14%)
- Artificial Intelligence 5 (14%)
Stage
- Series B 12 (34%)
- Series A 9 (26%)
- Series C 6 (17%)
- Seed 3 (9%)
- Series D 2 (6%)
Country
- South Korea 20 (57%)
- United States 9 (26%)
- Malaysia 1 (3%)
- Indonesia 1 (3%)
- Singapore 1 (3%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| LINER is Asia’s first AI Agent that helps users accomplish more with less time and effort “AI Workspace”, known as the autonomous agent, performs various and complex tasks requested by users using LLM-based AI, differentiated by LINER’s highlighter database. More than 94% of LINER's users are from outside Korea & more than 100 countries.We are reducing our customer’s research time from hundreds of minutes to tens of seconds every day with our product. | $36.1M / Series C / Aug 25, 2026 | ||
| LINER is Asia’s first AI Agent that helps users accomplish more with less time and effort “AI Workspace”, known as the autonomous agent, performs various and complex tasks requested by users using LLM-based AI, differentiated by LINER’s highlighter database. More than 94% of LINER's users are from outside Korea & more than 100 countries.We are reducing our customer’s research time from hundreds of minutes to tens of seconds every day with our product. | $29M / Series B / Oct 11, 2024 | ||
| AIMEDBIO provides therapeutic solutions to patients with serious brain diseases. | $29.2M / Series B / Jul 31, 2024 | ||
Linq
|
We are creating ‘hyper-automated insurance platforms’ to comprehensively support underwriters and claim adjusters and to facilitate communication between insurers and reinsurers using AI and deep learning. | $6.6M / Seed / Jun 11, 2024 | |
| Feature is a digital platform that enables generational IP and storytellers to thrive in the Web3 space. They work with forward-thinking creators and companies to create experiences that push the boundaries of what is possible. Feature is headquartered in Los Angeles, California. | $1.9M / Seed / May 26, 2024 | ||
| Mobilint is an AI semiconductor company focused on developing low-power neural processing units (NPUs) and edge AI chips for on-device artificial intelligence applications. Its technology supports AI computing, vision processing, robotics, surveillance systems, and industrial devices. The company aims to improve AI efficiency and reduce energyconsumption across edge computing environments. | $15.2M / Series B / Jan 04, 2024 | ||
| Clodot is an information technology company. | $8.4M / Venture - Series Unknown / Dec 19, 2023 | ||
| OncoResponse Inc., an immuno-oncology company located in Houston, Texas, has partnered with MD Anderson Cancer Center (MDACC) to deploy a unique and transformational approach to cancer therapeutic monoclonal antibody and target discovery. The company licensed the I-STAR™ platform, developed and validated by Theraclone Sciences of Seattle, tointerrogate the human memory B-cell repertoire of cancer patients who are considered “Elite Responders” to immunotherapy; as such, their own adaptive immune system responded to immunotherapy stimulation in a way that achieved curative or durable responses. From these Elite Responders, OncoResponse is leveraging the human immune system to identify fully human monoclonal antibodies and discover novel targets that will lead to the development of fully human antibody derived therapeutics for the treatment of cancer. | $14M / Series D / May 18, 2023 | ||
| WIRobotics is a Wearable robot that lessen physical demands on your body to safely allow active motion. | $3M / Seed / Apr 21, 2023 | ||
| Fazz enables merchants from SMEs to Enterprises to accept payments, transfer, bank, and invest. The firm offers Fazz Agen, an agent-based financial application serving micro and small businesses in Indonesia. Fazz Business is a business account to help startups, MSMEs, and large corporations build, run, and grow their businesses across SoutheastAsia by providing the ability to pay and receive payments, grow capital, and get funding.The company was founded in 2016 and is based in Singapore and Indonesia. PayFazz and Xfers merged and formed Fazz. | $75M / Series C / Sep 14, 2022 | ||
| See all 35 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does InterVest invest in?
InterVest invests primarily in Health Care, Software and Biotechnology startups, most often at Series B and Series A stage. Most of the 35 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is InterVest's check size?
InterVest typically joins rounds of $2.5M–$36M at Series A, $3M–$30M at Series B and $14M–$75M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds InterVest participates in.
When did InterVest last invest?
The most recent investment recorded for InterVest closed in Aug 2026. Shizune tracks 35 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
